The estimated Net Worth of Edward T Mathers is at least $394 ezer dollars as of 21 June 2024. Mr. Mathers owns over 3,000 units of Rhythm Pharmaceuticals stock worth over $147,930 and over the last 13 years he sold RYTM stock worth over $0. In addition, he makes $245,843 as Independent Director at Rhythm Pharmaceuticals.
Sign up
Mr. Mathers RYTM stock SEC Form 4 insiders trading
Edward has made over 2 trades of the Rhythm Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 3,000 units of RYTM stock worth $147,930 on 21 June 2024.
The largest trade he's ever made was buying 333,333 units of Rhythm Pharmaceuticals stock on 17 July 2023 worth over $999,999. On average, Edward trades about 7,007 units every 7 days since 2011. As of 21 June 2024 he still owns at least 3,000 units of Rhythm Pharmaceuticals stock.
You can see the complete history of Mr. Mathers stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Edward Mathers biography
Edward T. Mathers serves as Independent Director of the Company. Mr. Mathers has served as a member of our Board since 2013. He has been a Partner at New Enterprise Associates, a venture capital firm, since 2008, and has also served as General Partner since October 2019. Mr. Mathers currently serves on the boards of directors of ObsEva SA, Trevi Therapeutics, Inc., Mirum Pharmaceuticals, Inc., and Synlogic, Inc.. Mr. Mathers also serves on the boards of directors of numerous private companies, including Akouos, Inc., Amplyx Pharmaceuticals, Inc., Envisia Therapeutics Inc., Inozyme Pharma, Inc., Shape Therapeutics, Inc., Reneo Pharmaceuticals, Inc., and Senti Biosciences Inc. Mr. Mathers previously served on the board of directors of Ra Pharmaceuticals, Inc. until its acquisition by UCB in April 2020 and Liquidia Technologies, Inc. until May 2019. Prior to joining New Enterprise Associates, Mr. Mathers served in various corporate development roles at MedImmune, Inc., a biotechnology company that was acquired by AstraZeneca PLC in 2007, culminating in the position of Executive Vice President, Corporate Development and Venture. In this role, he also led the company's venture capital subsidiary, MedImmune Ventures, Inc., from 2002 to 2008. Mr. Mathers was a director of MedImmune, LLC, from 2007 to 2008. From 2000 to 2002, Mr. Mathers was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems, Inc., a biopharmaceutical company, which is now known as Nektar Therapeutics, Inc. Previously, for 15 years, Mr. Mathers was at Glaxo Wellcome, Inc., where he held sales and marketing positions of increasing responsibility. Mr. Mathers received a B.S. in chemistry from North Carolina State University.
What is the salary of Edward Mathers?
As the Independent Director of Rhythm Pharmaceuticals, the total compensation of Edward Mathers at Rhythm Pharmaceuticals is $245,843. There are 13 executives at Rhythm Pharmaceuticals getting paid more, with Hunter Smith having the highest compensation of $1,922,850.
How old is Edward Mathers?
Edward Mathers is 60, he's been the Independent Director of Rhythm Pharmaceuticals since 2013. There are 5 older and 13 younger executives at Rhythm Pharmaceuticals. The oldest executive at Rhythm Pharmaceuticals Inc. is Dr. David P. Meeker M.D., 67, who is the Chairman, Pres & CEO.
What's Edward Mathers's mailing address?
Edward's mailing address filed with the SEC is 104 5TH AVE, , NEW YORK, NY, 10011.
Insiders trading at Rhythm Pharmaceuticals
Over the last 13 years, insiders at Rhythm Pharmaceuticals have traded over $83,445,563 worth of Rhythm Pharmaceuticals stock and bought 6,290,000 units worth $106,961,700 . The most active insiders traders include Forest Baskett, Scott D Sandell és Peter J Barris. On average, Rhythm Pharmaceuticals executives and independent directors trade stock every 17 days with the average trade being worth of $3,358,405. The most recent stock trade was executed by Pamela J. Cramer on 9 September 2024, trading 4,099 units of RYTM stock currently worth $77,963.
What does Rhythm Pharmaceuticals do?
rhythm pharmaceuticals inc. is a biotechnology company located in 855 boylston street, 11th floor, boston, ma, united states.
What does Rhythm Pharmaceuticals's logo look like?
Complete history of Mr. Mathers stock trades at Savara Inc, Rhythm Pharmaceuticals, Synlogic Inc, Liquidia Corp, Mirum Pharmaceuticals Inc, Trevi Therapeutics, Akouos, Inozyme Pharma és Bright Health
Rhythm Pharmaceuticals executives and stock owners
Rhythm Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Hunter Smith,
Chief Financial Officer -
Dr. David P. Meeker M.D.,
Chairman, Pres & CEO -
Yann Mazabraud,
Exec. VP & Head of International -
Hunter C. Smith M.B.A.,
CFO & Treasurer -
Hunter C. Smith,
CFO, Treasurer & Sec. -
Jennifer L. Chien,
Exec. VP & Head of North America -
Joseph Shulman,
Chief Technical Officer -
Jennifer Good,
Independent Director -
Stuart Arbuckle,
Independent Director -
David Meeker,
Chairman of the Board, President, Chief Executive Officer -
David McGirr,
Independent Director -
Christophe Jean,
Independent Director -
Todd Foley,
Independent Director -
Edward Mathers,
Independent Director -
Dr. David P. Meeker,
Chairman, Pres & CEO -
Yann Mazabraud,
Executive Vice President, Head of International -
Hannah Deresiewicz,
IR Contact Officer -
Pamela Cramer,
Chief HR Officer -
Sarah Ryan,
VP of Sales & Marketing -
William T. Roberts,
Chief Accounting Officer -
Dr. Alastair Garfield Ph.D.,
VP & Head of Research -
Dr. Murray W. Stewart M.D.,
Chief Medical Officer -
Simon D. Kelner,
Chief HR Officer -
Satej Bhandarkar,
Sr. VP of Program Management, Strategy & Corp. Devel. -
Jim Flaherty,
Sr. VP & Gen. Counsel -
David Connolly,
Head of Investor Relations & Corp. Communications -
Rock Ventures Lp Third Rock...,
-
Fred T. Fiedorek,
Chief Medical Officer -
Nithya Desikan,
Chief Commercial Officer -
Der Ploeg Leonardus H.T. Van,
Chief Scientific Officer -
Neil Exter,
Director -
Rock Ventures Lp Third Rock...,
-
Bioventures V, L.P.Evnin Lu...,
-
Ravi Viswanathan,
10% owner -
Scott D Sandell,
10% owner -
David M Mott,
10% owner -
Patrick J Kerins,
10% owner -
Forest Baskett,
10% owner -
Peter J Barris,
10% owner -
M James Barrett,
10% owner -
Enterprise Associates 13 Lp...,
-
Inc Pfizer,
10% owner -
S.A. Ipsen,,
10% owner -
Advisors Llc Orbi Med Capit...,
-
Jonathan Silverstein,
Director -
Harbor Master Investors (Ca...,
10% owner -
James E Deerfield Mgmt L.P....,
-
Bros. Advisors Lp Baker Bro...,
-
Simon Kelner,
Chief Human Resources Officer -
Murray Stewart,
Chief Medical Officer -
Advisors Llc Orbi Med Capit...,
-
William T. Roberts,
Chief Accounting Officer -
Keith Michael Gottesdiener,
CEO & President -
Capital Management, L.P.Ra ...,
-
Jennifer Kayden Lee,
EVP, Head of North America -
Joseph Shulman,
Chief Technical Officer -
Lynn A. Tetrault,
Director -
Pamela J. Cramer,
Chief Human Resources Officer -
Linda Shapiro Manning,
Chief Medical Officer -
Christopher Paul German,
Corporate Controller & CAO -
Alastair Garfield,
Chief Scientific Officer